1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (7820)
  2. Meeting Abstract (3612)
  3. Review (610)
  4. Editorial (251)
  5. Book Section (189)
  6. Conference Paper (160)
  7. Research Letter (133)
  8. Correspondence (63)
  9. Miscellaneous (62)
  10. Guidelines (30)
  11. Book Whole (6)
Groups
  1. Sloan Kettering Institute Postdocs (12936)
  2. GSK Faculty (6210)
  3. Department of Medicine (4656)
  4. Sloan Kettering Institute Faculty (3490)
  5. Surgery (2557)
  6. Solid Tumor Oncology Division (2525)

More Groups

People
  1. Britta Weigelt (366)
  2. Jorge Reis-Filho (327)
  3. Mithat Gonen (309)
  4. Marc Ladanyi (304)
  5. Joseph Deasy (278)
  6. Michael Berger (278)

More People

Years
  1. 2025 (394)
  2. 2024 (1038)
  3. 2023 (1151)
  4. 2022 (1364)
  5. 2021 (1176)
  6. 2020 (1240)

More Years

Publications
  1. Blood (641)
  2. Cancer Research (542)
  3. Journal of Clinical Oncology (416)
  4. Journal of Nuclear Medicine (261)
  5. Annals of Surgical Oncology (257)
  6. Clinical Cancer Research (235)

More Publications

Publishers
  1. Nature Publishing Group (1308)
  2. Elsevier Inc. (1173)
  3. American Association for Cancer Research (1039)
  4. Springer (818)
  5. Cell Press (719)
  6. American Society of Hematology (697)

More Publishers

Results (12936)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fructose treatment targets myeloid leukemogenesis in IDH2 mutants by exhausting alpha-ketoglutarate pools
    Meeting Abstract

    Savino, A. M.; Turner, B.; Jeong, S.; Schild, T.; Yang, X.; Luo, H.; Chirayil, R.; Cullen, Q.; Chan, M.; Han, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Transient M-proteins: Epidemiology, causes, and the impact of mass spectrometry: The iStopMM study
    Meeting Abstract

    Palmason, R.; Berlanga, O.; Sigurdsson, J. K.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Levy, M.; Reed, E. R.; Þórir Oskarsson, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Systematic evaluation of AML-associated antigens identifies novel anti-U5 snRNP200 therapeutic antibodies for the treatment of AML
    Meeting Abstract

    Knorr, K.; Erickson, C.; Wang, E.; Rahman, J.; Mi, X.; Lu, S.; Fox, N.; Penson, A.; Hogg, S.; Stanley, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
    Meeting Abstract

    Robinson, T.; Bowman, R. L.; Persaud, S.; Liu, Y.; Gao, Q.; Zhang, J. P.; Sun, X.; Sciambi, A.; Llanso, A.; Famulare, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia
    Meeting Abstract

    Cruz-Rodriguez, N.; Kotini, A. G.; Carcamo, S.; Olszewska, M.; Bernard, E.; Luo, H.; Kharas, M. G.; Hasson, D.; Papapetrou, E. P.
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save